An assessment of the load modifying potential of model predictive controlled dynamic facades within the California context

California is making major strides towards meeting its greenhouse gas emission reduction goals with the transformation of its electrical grid to accommodate renewable generation, aggressive promotion of building energy efficiency, and increased emphasis on moving toward electrification of end uses (e.g., residential heating, etc.). As a result of this activity, the State is faced with significant challenges of systemwide resource adequacy, power quality and grid reliability that could be addressed in part with demand responsive (DR) load modifying strategies using controllable building technologies. Dynamic facades have the ability to potentially shift and shed loads at critical times of the day in combination with daylighting and HVAC controls. This study explores the technical potential of dynamic facades to support net load shape objectives. A model predictive controller (MPC) was designed based on reduced order thermal (Modelica) and window (Radiance) models. Using an automated workflow (involving JModelica.org and MPCPy), these models were converted and differentiated to formulate a non-linear optimization problem. A gradient-based, non-linear programming problem solver (IPOPT) was used to derive an optimal control strategy, then a post-optimization step was used to convert the solution to a discrete state for facade actuation. Continuous state modulation of the façade was also modeled. The performance of the MPC controller with and without activation of thermal mass was evaluated in a south-facing perimeter office zone with a three-zone electrochromic window for a clear sunny week during summer and winter periods in Oakland and Burbank, California. MPC strategies reduced total energy cost by 9–28% and critical coincident peak demand was reduced by up to 0.58 W/ft2-floor or 19–43% in the 4.6 m (15 ft) deep south zone on sunny summer days in Oakland compared to state-of-the-art heuristic control. Similar savings were achieved for the hotter, Burbank climate in Southern California. This outcome supports the argument that MPC control of dynamic facades can provide significant electricity cost reductions and net load management capabilities of benefit to both the building owner and evolving electrical grid

An assessment of the load modifying potential of model predictive controlled dynamic facades within the California context

California is making major strides towards meeting its greenhouse gas emission reduction goals with the transformation of its electrical grid to accommodate renewable generation, aggressive promotion of building energy efficiency, and increased emphasis on moving toward electrification of end uses (e.g., residential heating, etc.). As a result of this activity, the State is faced with significant challenges of systemwide resource adequacy, power quality and grid reliability that could be addressed in part with demand responsive (DR) load modifying strategies using controllable building technologies. Dynamic facades have the ability to potentially shift and shed loads at critical times of the day in combination with daylighting and HVAC controls. This study explores the technical potential of dynamic facades to support net load shape objectives. A model predictive controller (MPC) was designed based on reduced order thermal (Modelica) and window (Radiance) models. Using an automated workflow (involving JModelica.org and MPCPy), these models were converted and differentiated to formulate a non-linear optimization problem. A gradient-based, non-linear programming problem solver (IPOPT) was used to derive an optimal control strategy, then a post-optimization step was used to convert the solution to a discrete state for facade actuation. Continuous state modulation of the façade was also modeled. The performance of the MPC controller with and without activation of thermal mass was evaluated in a south-facing perimeter office zone with a three-zone electrochromic window for a clear sunny week during summer and winter periods in Oakland and Burbank, California. MPC strategies reduced total energy cost by 9–28% and critical coincident peak demand was reduced by up to 0.58 W/ft2-floor or 19–43% in the 4.6 m (15 ft) deep south zone on sunny summer days in Oakland compared to state-of-the-art heuristic control. Similar savings were achieved for the hotter, Burbank climate in Southern California. This outcome supports the argument that MPC control of dynamic facades can provide significant electricity cost reductions and net load management capabilities of benefit to both the building owner and evolving electrical grid

CyDER–an FMI-based co-simulation platform for distributed energy resources

The increased integration of distributed energy resources (DERs) is bringing a number of challenges to the power grid. These include reverse power flows in distribution systems and potentially transmission systems and grid stability. So far, specialized tools have been developed to capture some of the impact of DERs at the distribution level. However, distribution system operators lack visibility into the overall system conditions. Furthermore, the impact of increasing DERs is not limited to the distribution level but also influences the transmission grid. To support the planning and operation of the grid, we developed a co-simulation platform called CyDER (A Cyber Physical Co-simulation Platform for Distributed Energy Resources in Smart Grids) that integrates various domain-specific simulation tools. CyDER is based on the functional mock-up interface standard. This paper gives an overview of CyDER and demonstrates its use based on two applications

CyDER–an FMI-based co-simulation platform for distributed energy resources

The increased integration of distributed energy resources (DERs) is bringing a number of challenges to the power grid. These include reverse power flows in distribution systems and potentially transmission systems and grid stability. So far, specialized tools have been developed to capture some of the impact of DERs at the distribution level. However, distribution system operators lack visibility into the overall system conditions. Furthermore, the impact of increasing DERs is not limited to the distribution level but also influences the transmission grid. To support the planning and operation of the grid, we developed a co-simulation platform called CyDER (A Cyber Physical Co-simulation Platform for Distributed Energy Resources in Smart Grids) that integrates various domain-specific simulation tools. CyDER is based on the functional mock-up interface standard. This paper gives an overview of CyDER and demonstrates its use based on two applications

A framework to measure the technical, economic, and rate impacts of distributed solar, electric vehicles, and storage

This study explores the joint impacts across the power system of distributed energy resources (DER) that could be deployed in utility distribution systems through an analysis of generation, transmission, and distribution expansion and costs driven by DER adoption. We identify six adoption scenarios that combine deployment levels of rooftop solar photovoltaic modules (PV), electric vehicle charging (EV), and battery storage in residential and commercial customers connected to representative feeders in Indiana by 2025 and 2040. Indiana is a good proxy for many U.S. states with low current DER adoption but potentially high future growth. The economic value of DER is assessed by developing capacity expansion and power flow analysis of the generation and distribution segments, respectively, under future hourly demand assumptions based on each adoption scenarios. Results for the distribution system power flow simulations show that voltage violations are relatively rare. Voltage violations can be mitigated at a very low cost using a combination of smart inverters in future rooftop PV systems and voltage adjustments in the feeder heads. Line loading issues are minimal, with only 0.2% of simulation hours showing loading levels above 100% of capacity. Generation capacity impacts are driven by unmanaged EV charging and could be mitigated with charging management. We estimate that the incremental rate impact from power system investment and operation of increased DER adoption in Indiana will be between −1.6% to + 2% in 2025 and + 0.2% to + 15% in 2040 relative to the base case

Paracetamol Medication During Pregnancy: Insights on Intake Frequencies, Dosages and Effects on Hematopoietic Stem Cell Populations in Cord Blood From a Longitudinal Prospective Pregnancy Cohort

Background: Paracetamol is the first choice for antipyretic or analgesic treatment throughout pregnancy. Products with Paracetamol are readily available over the counter and therefore easily accessible for self-medication. Epidemiological data on Paracetamol intake pattern during pregnancy and its potential immunological effects are sparse. We aimed to analyze a possible association between Paracetamol medication and numbers of hematopoietic stem cells (HSC) in cord blood. Methods: The objective was addressed in the PRINCE (PRENATAL DETERMINANTS OF CHILDREN'S HEALTH) study, a population-based prospective pregnancy cohort study initiated in 2011 at the University Medical Center in Hamburg, Germany. 518 healthy pregnant women with singleton pregnancies were recruited during the first trimester. Three examinations were scheduled at the end of the 1st (gestational week 12–14), the 2nd (gestational week 22–24) and the 3rd trimester (gestational week 34–36). For 146 of these women, cord blood flow cytometry data were available. Paracetamol intake was assessed for each trimester of pregnancy. Findings: Among the 518 enrolled women, 40% took Paracetamol as main analgesic treatment during pregnancy. The intake frequency and dosage of Paracetamol varied between the women and was overall low with a tendency towards higher frequencies and higher dosages in the third trimester. Paracetamol intake, particularly during the third trimester, resulted in decreased relative numbers of HSCs in cord blood, independent of maternal age, first-trimester BMI, parity, gestational age and birth weight (−0.286 (95% CI −0.592, 0.021), p = 0.068). Interpretation: Prenatal Paracetamol intake, especially during the third trimester, may be causally involved in decreasing HSCs in cord blood

BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells.

The transcription factor BCL11B is essential for development of the nervous and the immune system, and Bcl11b deficiency results in structural brain defects, reduced learning capacity, and impaired immune cell development in mice. However, the precise role of BCL11B in humans is largely unexplored, except for a single patient with a BCL11B missense mutation, affected by multisystem anomalies and profound immune deficiency. Using massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in BCL11B. Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency. Six frameshift mutations, two nonsense mutations, one missense mutation, and two chromosomal rearrangements resulting in diminished BCL11B expression, arose de novo. A further frameshift mutation was transmitted from a similarly affected mother. Interestingly, the most severely affected patient harbours a missense mutation within a zinc-finger domain of BCL11B, probably affecting the DNA-binding structural interface, similar to the recently published patient. Furthermore, the most C-terminally located premature termination codon mutation fails to rescue the progenitor cell proliferation defect in hippocampal slice cultures from Bcl11b-deficient mice. Concerning the role of BCL11B in the immune system, extensive immune phenotyping of our patients revealed alterations in the T cell compartment and lack of peripheral type 2 innate lymphoid cells (ILC2s), consistent with the findings described in Bcl11b-deficient mice. Unsupervised analysis of 102 T lymphocyte subpopulations showed that the patients clearly cluster apart from healthy children, further supporting the common aetiology of the disorder. Taken together, we show here that mutations leading either to BCL11B haploinsufficiency or to a truncated BCL11B protein clinically cause a non-syndromic neurodevelopmental delay. In addition, we suggest that missense mutations affecting specific sites within zinc-finger domains might result in distinct and more severe clinical outcomes

BCL11B mutations in patients affected by a neurodevelopmental disorder with reduced type 2 innate lymphoid cells

The transcription factor BCL11B is essential for development of the nervous and the immune system, and Bcl11b deficiency results in structural brain defects, reduced learning capacity, and impaired immune cell development in mice. However, the precise role of BCL11B in humans is largely unexplored, except for a single patient with a BCL11B missense mutation, affected by multisystem anomalies and profound immune deficiency. Using massively parallel sequencing we identified 13 patients bearing heterozygous germline alterations in BCL11B. Notably, all of them are affected by global developmental delay with speech impairment and intellectual disability; however, none displayed overt clinical signs of immune deficiency. Six frameshift mutations, two nonsense mutations, one missense mutation, and two chromosomal rearrangements resulting in diminished BCL11B expression, arose de novo. A further frameshift mutation was transmitted from a similarly affected mother. Interestingly, the most severely affected patient harbours a missense mutation within a zinc-finger domain of BCL11B, probably affecting the DNA-binding structural interface, similar to the recently published patient. Furthermore, the most C-terminally located premature termination codon mutation fails to rescue the progenitor cell proliferation defect in hippocampal slice cultures from Bcl11b-deficient mice. Concerning the role of BCL11B in the immune system, extensive immune phenotyping of our patients revealed alterations in the T cell compartment and lack of peripheral type 2 innate lymphoid cells (ILC2s), consistent with the findings described in Bcl11b-deficient mice. Unsupervised analysis of 102 T lymphocyte subpopulations showed that the patients clearly cluster apart from healthy children, further supporting the common aetiology of the disorder. Taken together, we show here that mutations leading either to BCL11B haploinsufficiency or to a truncated BCL11B protein clinically cause a non-syndromic neurodevelopmental delay. In addition, we suggest that missense mutations affecting specific sites within zinc-finger domains might result in distinct and more severe clinical outcomes

Limited clinical relevance of imaging techniques in the follow-up of patients with advanced chronic lymphocytic leukemia: results of a meta-analysis

The clinical value of imaging is well established for the follow-up of many lymphoid malignancies but not for chronic lymphocytic leukemia (CLL). A meta-analysis was performed with the dataset of 3 German CLL Study Group phase 3 trials (CLL4, CLL5, and CLL8) that included 1372 patients receiving first-line therapy for CLL. Response as well as progression during follow-up was reassessed according to the National Cancer Institute Working Group1996 criteria. A total of 481 events were counted as progressive disease during treatment or follow-up. Of these, 372 progressions (77%) were detected by clinical symptoms or blood counts. Computed tomography (CT) scans or ultrasound were relevant in 44 and 29 cases (9% and 6%), respectively. The decision for relapse treatment was determined by CT scan or ultrasound results in only 2 of 176 patients (1%). CT scan results had an impact on the prognosis of patients in complete remission only after the administration of conventional chemotherapy but not after chemoimmunotherapy. In conclusion, physical examination and blood count remain the methods of choice for staging and clinical follow-up of patients with CLL as recommended by the International Workshop on Chronic Lymphocytic Leukemia 2008 guidelines. These trials are registered at http://www.isrctn.org as ISRCTN 75653261 and ISRCTN 36294212 and at http://www.clinicaltrials.gov as NCT00281918